Rheumatoid Arthritis: The Daily PANCE Blueprint
A 38-year-old woman presents for a follow-up visit concerning persistent joint pain and stiffness in her hands, which she has experienced for the past six months. Laboratory findings reveal elevated C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), positive rheumatoid factor (RF), and positive anti-cyclic citrullinated peptide (anti-CCP). X-rays demonstrate joint destruction. She has not yet received any treatment for her symptoms. What is the most appropriate initial treatment for this patient?
A. Tumor necrosis factor inhibitors
B. Systemic corticosteroids
C. Nonsteroidal anti-inflammatory drugs
D. Disease-modifying antirheumatic drugs
E. Interleukin-1 inhibitors
Answer and topic summary
The answer is D. Disease-modifying antirheumatic drugs
Disease-modifying antirheumatic drugs (DMARDs) are considered the first-line treatment for rheumatoid arthritis, especially in patients presenting with signs of joint destruction and positive autoantibodies. DMARDs, including methotrexate, hydroxychloroquine, and sulfasalazine, are crucial for slowing the progression of the disease and preventing further joint damage. Early initiation of DMARDs is essential to prevent long-term complications and irreversible joint damage.
Incorrect Answers:
- A. Tumor necrosis factor inhibitors: These are biologic agents typically reserved for patients who do not respond adequately to DMARDs. They are not usually first-line therapy due to potential side effects and high costs.
- B. Systemic corticosteroids: While corticosteroids can help manage acute inflammation and symptoms, they are not recommended for long-term use due to risks such as osteoporosis, hyperglycemia, and hypertension. They may be used as a short-term bridge until DMARDs take effect.
- C. Nonsteroidal anti-inflammatory drugs: NSAIDs are effective for pain relief but do not alter the disease course of rheumatoid arthritis. They are often used alongside DMARDs to manage symptoms.
- E. Interleukin-1 inhibitors: IL-1 inhibitors are less commonly used and are typically considered only after failure of other therapies, including TNF inhibitors and other biologics. They are not first-line treatments for rheumatoid arthritis.
View blueprint lesson
Smarty PANCE Content Blueprint Review:
Covered under ⇒ PANCE Blueprint Musculoskeletal ⇒ ⇒
Also covered in the Internal Medicine and Family Medicine PAEA EOR topic lists
